Norinchukin Bank The raised its holdings in Danaher Co. (NYSE:DHR) by 4.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 151,114 shares of the conglomerate’s stock after acquiring an additional 6,923 shares during the period. Norinchukin Bank The’s holdings in Danaher were worth $19,950,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of the business. Vanguard Group Inc lifted its holdings in shares of Danaher by 1.4% in the 3rd quarter. Vanguard Group Inc now owns 44,738,984 shares of the conglomerate’s stock worth $4,861,338,000 after acquiring an additional 605,018 shares during the last quarter. Gamco Investors INC. ET AL boosted its holdings in shares of Danaher by 1.6% in the fourth quarter. Gamco Investors INC. ET AL now owns 9,350 shares of the conglomerate’s stock valued at $964,000 after acquiring an additional 150 shares in the last quarter. Advisors Asset Management Inc. boosted its holdings in shares of Danaher by 2.8% in the fourth quarter. Advisors Asset Management Inc. now owns 40,082 shares of the conglomerate’s stock valued at $4,133,000 after acquiring an additional 1,082 shares in the last quarter. Crossmark Global Holdings Inc. boosted its holdings in shares of Danaher by 4.4% in the fourth quarter. Crossmark Global Holdings Inc. now owns 71,552 shares of the conglomerate’s stock valued at $7,378,000 after acquiring an additional 3,040 shares in the last quarter. Finally, Parkside Financial Bank & Trust boosted its holdings in shares of Danaher by 76.7% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,016 shares of the conglomerate’s stock valued at $105,000 after acquiring an additional 441 shares in the last quarter. 78.82% of the stock is owned by hedge funds and other institutional investors.
Shares of Danaher stock traded up $0.87 during midday trading on Friday, hitting $142.85. The company had a trading volume of 3,777,800 shares, compared to its average volume of 2,698,431. Danaher Co. has a 1-year low of $94.59 and a 1-year high of $144.57. The company has a market cap of $101.41 billion, a PE ratio of 31.60, a PEG ratio of 2.72 and a beta of 0.95. The company has a current ratio of 2.18, a quick ratio of 1.74 and a debt-to-equity ratio of 0.32. The company’s 50 day moving average price is $135.57.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.48%. The ex-dividend date is Thursday, June 27th. Danaher’s dividend payout ratio is 15.04%.
In related news, Director Donald J. Ehrlich sold 5,000 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $132.95, for a total transaction of $664,750.00. Following the completion of the sale, the director now directly owns 100,603 shares in the company, valued at approximately $13,375,168.85. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Thomas Patrick Joyce, Jr. sold 183,878 shares of the company’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $131.30, for a total value of $24,143,181.40. Following the sale, the chief executive officer now owns 302,377 shares of the company’s stock, valued at $39,702,100.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 453,448 shares of company stock worth $59,724,640. Insiders own 11.40% of the company’s stock.
Several brokerages recently commented on DHR. Zacks Investment Research cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd. Needham & Company LLC restated a “buy” rating and set a $141.00 target price (up previously from $138.00) on shares of Danaher in a research report on Wednesday, April 17th. Piper Jaffray Companies began coverage on shares of Danaher in a research report on Tuesday, June 11th. They set a “neutral” rating and a $148.00 target price for the company. JPMorgan Chase & Co. reiterated an “overweight” rating and set a $140.00 price target on shares of Danaher in a report on Monday, March 4th. Finally, Wolfe Research began coverage on shares of Danaher in a report on Thursday, May 30th. They set an “outperform” rating for the company. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Danaher presently has a consensus rating of “Buy” and an average price target of $133.00.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Featured Story: Should You Consider an Index Fund?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.